Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
Age \> 18 years
Confirmed melanoma
Patient has been prescribed Intron A therapy for High-Risk Stage II \& III Melanoma
Intron A therapy started within 70 days of surgery (additional 15 days may be granted by the sponsor upon written approval)
Proper contraception in both male and female subjects and the female partner(s) of male study subjects
You may not be if
Metastatic disease at the time of diagnosis
Other malignancies
History of non compliance to other therapies
Pregnancy or breast feeding
Previous Intron A therapy
Clareo Health | Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
